Kelli Overway, APRN
Nurse Practitioner · Midland, MINPI 1013510700
Payments from drug & device makers
Across 385 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Lilly USA, LLC$848
- Boehringer Ingelheim$803
- Abbott$634
- AstraZeneca$562
- Sanofi-aventis U.S. LLC$541
- plus $3K from 34 others
What the payments were for
- Travel & lodging$90612%
- Food & beverage$6,90488%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,229 |
| Lilly USA, LLC | 46 | $848 |
| Boehringer Ingelheim | 47 | $803 |
| Abbott | 36 | $634 |
| AstraZeneca(2 entities) | 29 | $562 |
| Sanofi-aventis U.S. LLC | 29 | $541 |
| Amgen(2 entities) | 25 | $433 |
| Mannkind Corporation | 16 | $284 |
| Novo Nordisk | 17 | $281 |
| AbbVie | 16 | $266 |
| Bayer | 8 | $150 |
| Dexcom, Inc. | 8 | $149 |
| Amarin Pharma, Inc. | 8 | $135 |
| Esperion Therapeutics, Inc. | 8 | $118 |
| Zealand Pharma US, Inc. | 6 | $112 |
| Amneal Pharmaceuticals LLC | 7 | $104 |
| Merck | 6 | $91 |
| Endo Pharmaceuticals Inc. | 5 | $89 |
| Radius Health, Inc. | 5 | $88 |
| Lifescan, Inc. | 5 | $84 |
| Insulet Corporation | 4 | $78 |
| IBSA Pharma Inc. | 4 | $70 |
| Antares Pharma, Inc. | 4 | $69 |
| GRT US Holding, Inc. | 3 | $68 |
| Recordati_rare_diseases_inc. | 2 | $66 |
| Tandem Diabetes Care, Inc. | 4 | $65 |
| Tolmar, Inc. | 3 | $62 |
| Ultragenyx Pharmaceutical Inc. | 3 | $45 |
| BD | 2 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $40 |
| Intuity Medical Inc | 2 | $35 |
| Althera Pharmaceuticals LLC | 2 | $31 |
| Clarus Therapeutics Inc. | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $27 |
| Cequr Corporation | 2 | $26 |
| Nevro Corp. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$803
- MOUNJARO$125
How this compares
$7,821 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 145 | $188,442 |
| TrulicityDulaglutide | 128 | $186,615 |
| OzempicSemaglutide | 75 | $128,777 |
| JardianceEmpagliflozin | 91 | $112,388 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $49,765 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $45,387 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $33,080 |
| FarxigaDapagliflozin Propanediol | 22 | $33,046 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $28,383 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $22,537 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $16,465 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $16,338 |
| Humalog Kwikpen U-100Insulin Lispro | 40 | $13,026 |
| JanuviaSitagliptin Phosphate | 16 | $12,505 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $11,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $848 | $384,174302 claims |
| Novo NordiskOzempic, Novolog | $281 | $137,08298 claims |
| Boehringer IngelheimJardiance | $803 | $112,38891 claims |
| AstraZenecaFarxiga | $562 | $33,04622 claims |
| MerckJanuvia | $91 | $12,50516 claims |
| Sanofi-aventis U.S. LLCLantus | $541 | $1,70613 claims |
| AbbVieSynthroid | $266 | $79312 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $104 | $47935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Midland
- Steven LaporteMidland$11K
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
- Lisa Astalos ChismWoodhaven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.